Review




Structured Review

Santa Cruz Biotechnology rap1
Rap1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 530 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rap1/RAP1+Antibody/pmc12993239-119-51-53
Average 94 stars, based on 530 article reviews
rap1 - by Bioz Stars, 2026-10
94/100 stars

Images

Related Articles

Pyrolysis Gas Chromatography:

Article Title: Modified hTERT treatment ameliorates pressure overload-induced heart failure.
Article Snippet: .. The primary antibodies: histone H 2 AX (1:1000, Cell Signalling Technology, 7631S), γH 2 AX (1:1000, Cell Signalling Technology, 9718S), 53BP1(1:1000, Cell Signalling Technology, 4937S), p53 (1:1000, Cell Signalling Technology, 2524S), Phospho-p53 (Ser15) (1:1000, Cell Signalling Technology, 9284s), PGC-1α (1:1000, Santa Cruz, sc-517380), TFAM (1:1000, Proteintech, 22586-1-AP), TRF1 (1:1000, Abcam, ab192629), RAP1 (1:1000, Santa Cruz, sc-53434), TIN2 (1:1000, Proteintech, 11368-1-AP), POT1 (1:1000, Novus Biologicals, NB500-176), HA-tag (1:1000, Cell Signalling Technology, 3724s), DYKDDDDK Tag (1:1000, Cell Signalling Technology, 14793s), H3 (1:1000, Cell Signalling Technology, D5A7), GAPDH (1:1000, Proteintech, 60004-1-Ig) followed by secondary antibody for 1 h with a 1:2000 dilution of IgG Goat Anti-Mouse HRP (Proteintech, SA00001-1) or IgG Goat Anti- Rabbit HRP (Proteintech, SA00001-2). .. Western blots were developed using ECL chemiluminescent substrate (Thermo Fisher Scientific, 34098CN).

Article Title: Modified hTERT treatment ameliorates pressure overload-induced heart failure
Article Snippet: .. The primary antibodies: histone H 2 AX (1:1000, Cell Signalling Technology, 7631S), γH 2 AX (1:1000, Cell Signalling Technology, 9718S), 53BP1(1:1000, Cell Signalling Technology, 4937S), p53 (1:1000, Cell Signalling Technology, 2524S), Phospho-p53 (Ser15) (1:1000, Cell Signalling Technology, 9284s), PGC-1α (1:1000, Santa Cruz, sc-517380), TFAM (1:1000, Proteintech, 22586-1-AP), TRF1 (1:1000, Abcam, ab192629), RAP1 (1:1000, Santa Cruz, sc-53434), TIN2 (1:1000, Proteintech, 11368-1-AP), POT1 (1:1000, Novus Biologicals, NB500-176), HA-tag (1:1000, Cell Signalling Technology, 3724s), DYKDDDDK Tag (1:1000, Cell Signalling Technology, 14793s), H3 (1:1000, Cell Signalling Technology, D5A7), GAPDH (1:1000, Proteintech, 60004-1-Ig) followed by secondary antibody for 1 h with a 1:2000 dilution of IgG Goat Anti-Mouse HRP (Proteintech, SA00001-1) or IgG Goat Anti- Rabbit HRP (Proteintech, SA00001-2). .. Western blots were developed using ECL chemiluminescent substrate (Thermo Fisher Scientific, 34098CN).

Concentration Assay:

Article Title: Elevated tissue status of omega-3 fatty acids protects against age-related telomere attrition in fat-1 transgenic mice.
Article Snippet: .. The used concentration and accession numbers of antibodies, were as follow: Ku70: 1:1000, NBP2-38954; TRF1: 1:1000, NB110-68281; TRF2: 1:1000, NB100-5650; TIN2: 1:1000, NB600-61522, (Novus Bio); TPP1: 1:1000, SC-377318; RAP1: 1:1000, SC-53434, (Santa Cruz Biotechnology, Santa Cruz, CA); POT1: 1:1000; PA5-75366; actin: 1:1000, MA5-11869, (Invitrogen, Camarillo, CA, USA). .. Whole blood samples were lysed with BD Pharm Lyse buffer (BD Biosciences, CA, USA) to remove red blood cells.

Incubation:

Article Title: Atractylodis Rhizoma-Atractylodis Macrocephala Rhizoma herbal pair restores intestinal mucosal barrier function in ulcerative colitis via activating Epac1/Rap1 pathway and inhibiting PI3K/AKT pathway
Article Snippet: .. Membranes were incubated overnight at 4 °C with primary antibodies: MUC2 (Proteintech, 1∶1000, 27675-1-AP), zonula occludens-1 (ZO-1, Proteintech, 1∶1000, 21773-1-AP), occludin (Proteintech, 1∶1000, 27260-1-AP), claudin-1 (Proteintech, 1∶1000, 28674-1-AP), MMP-2 (Proteintech, 1∶1000, 10373-2-AP), MMP-9 (Proteintech, 1∶1000, 10375-1-AP), Epac1 (Abclonal, 1∶1000, A4149), Rap1 (Santa Cruz, 1∶300, sc398755), PI3K (Proteintech, 1∶1000, 20584-1-AP), phosphorylated (p)-PI3K (Affinity, 1∶1000, AF4369), AKT (Pro- 315 teintech, 1∶1000, 10176-2-AP), and p-AKT (Proteintech, 1∶1000, 66444-1-Ig). .. The next day, membranes were incubated with βactin (Abclonal, 1∶10,000, AC026) as a secondary antibody.

Article Title: De novo interleukin-10 production primed by Lactobacillus sakei CVL-001 amplifies the immunomodulatory abilities of mesenchymal stem cells to alleviate colitis.
Article Snippet: Mesenchymal stem cells (MSCs) hold therapeutic promise for treating inflammatory bowel disease (IBD) owing to their immunomodulatory properties.. Currently, pre-conditioning strategies with several beneficial agents have been applied to enhance the efficacy of MSCs in treating IBDs.. Probiotics are increasingly acknowledged as supplemental therapy for IBD; however, their potential benefits in MSCs-based therapy remain largely unexplored.

Article Title: Mevalonate kinase-deficient THP-1 cells show a disease-characteristic pro-inflammatory phenotype.
Article Snippet: Electrophoresis was performed frontiersin.org in 3-(N-Morpholino) propanesulfonic acid (MOPS) running buffer, after which the proteins were transferred to a polyvinylidene difluoride (PVDF) membrane (for the primary antibody against unprenylated Rap1a) or to a nitrocellulose membrane (for all other primary antibodies) using the iBlot Dry Blotting System (iBlot 2 Gel Transfer Device). .. Membranes were blocked in 2% bovine serum albumin (BSA; Sigma) in TBS with 0.1% Tween-20 (TBS-T) for 1 hour at room temperature, followed by overnight incubation at 4°C with primary antibodies in 2% BSA in PBS-T. Primary antibodies were used against MK (1:5,000, own production (27), HMGCR (1:1,000, Atlas antibodies, AMAb90618), unprenylated Rap1a (1:500, Santa-Cruz, sc-373968), total Rap1 (1:500, Santa-Cruz, sc398755), SRC (1:1,000, Cell Signaling, 2110) and phosphorylated Src family kinases (Tyr416) (1:1,000, Cell Signaling, 2101). .. As loading control, membranes were incubated with a primary antibody against a-tubulin (1:2,000, Sigma-Aldrich, T6199).

Blocking Assay:

Article Title: De novo interleukin-10 production primed by Lactobacillus sakei CVL-001 amplifies the immunomodulatory abilities of mesenchymal stem cells to alleviate colitis.
Article Snippet: Mesenchymal stem cells (MSCs) hold therapeutic promise for treating inflammatory bowel disease (IBD) owing to their immunomodulatory properties.. Currently, pre-conditioning strategies with several beneficial agents have been applied to enhance the efficacy of MSCs in treating IBDs.. Probiotics are increasingly acknowledged as supplemental therapy for IBD; however, their potential benefits in MSCs-based therapy remain largely unexplored.

Transcranial Magnetic Stimulation:

Article Title: Mevalonate kinase-deficient THP-1 cells show a disease-characteristic pro-inflammatory phenotype.
Article Snippet: Electrophoresis was performed frontiersin.org in 3-(N-Morpholino) propanesulfonic acid (MOPS) running buffer, after which the proteins were transferred to a polyvinylidene difluoride (PVDF) membrane (for the primary antibody against unprenylated Rap1a) or to a nitrocellulose membrane (for all other primary antibodies) using the iBlot Dry Blotting System (iBlot 2 Gel Transfer Device). .. Membranes were blocked in 2% bovine serum albumin (BSA; Sigma) in TBS with 0.1% Tween-20 (TBS-T) for 1 hour at room temperature, followed by overnight incubation at 4°C with primary antibodies in 2% BSA in PBS-T. Primary antibodies were used against MK (1:5,000, own production (27), HMGCR (1:1,000, Atlas antibodies, AMAb90618), unprenylated Rap1a (1:500, Santa-Cruz, sc-373968), total Rap1 (1:500, Santa-Cruz, sc398755), SRC (1:1,000, Cell Signaling, 2110) and phosphorylated Src family kinases (Tyr416) (1:1,000, Cell Signaling, 2101). .. As loading control, membranes were incubated with a primary antibody against a-tubulin (1:2,000, Sigma-Aldrich, T6199).

Cell-Signaling:

Article Title: Mevalonate kinase-deficient THP-1 cells show a disease-characteristic pro-inflammatory phenotype.
Article Snippet: Electrophoresis was performed frontiersin.org in 3-(N-Morpholino) propanesulfonic acid (MOPS) running buffer, after which the proteins were transferred to a polyvinylidene difluoride (PVDF) membrane (for the primary antibody against unprenylated Rap1a) or to a nitrocellulose membrane (for all other primary antibodies) using the iBlot Dry Blotting System (iBlot 2 Gel Transfer Device). .. Membranes were blocked in 2% bovine serum albumin (BSA; Sigma) in TBS with 0.1% Tween-20 (TBS-T) for 1 hour at room temperature, followed by overnight incubation at 4°C with primary antibodies in 2% BSA in PBS-T. Primary antibodies were used against MK (1:5,000, own production (27), HMGCR (1:1,000, Atlas antibodies, AMAb90618), unprenylated Rap1a (1:500, Santa-Cruz, sc-373968), total Rap1 (1:500, Santa-Cruz, sc398755), SRC (1:1,000, Cell Signaling, 2110) and phosphorylated Src family kinases (Tyr416) (1:1,000, Cell Signaling, 2101). .. As loading control, membranes were incubated with a primary antibody against a-tubulin (1:2,000, Sigma-Aldrich, T6199).

other:

Article Title: EphrinB2 alleviates tubulointerstitial fibrosis in diabetic kidney disease
Article Snippet: Rap1 , 1:1000 , Santa Cruz , SC-398755.



Similar Products

95
MedChemExpress rap1 signaling
Rap1 Signaling, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rap1/GGTI298/pm42381078-64-5-11
Average 95 stars, based on 1 article reviews
rap1 signaling - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier

95
MedChemExpress rap1 inhibition
M2 microglia-derived migrasome-enriched EVs activate the <t>cAMP/EPAC1/Rap1</t> pathway to improve mitochondrial function in microglia. ( A ) Heatmap of differentially expressed genes in ipsilateral brain tissue between the MCAO and MIGs groups. ( B ) Volcano plot of DEGs between the MCAO and MIGs groups. ( C ) KEGG pathway enrichment analysis. The top enriched pathways are shown, with the cAMP signaling pathway and Rap1 signaling pathway highlighted. ( D ) cAMP levels in BV2 cells. ( E-G ) Representative immunofluorescence image and quantitative analysis of EPAC1 and Rap1 in BV2 cells. ( H, I ) Western blot analysis and quantification of EPAC1 and Rap1 protein expression in BV2 cells. ( J ) Representative TEM images of mitochondria in BV2 cells. ( K ) Representative images and quantification of mitochondrial mass. (L, M ) Representative images and quantification of mitochondrial superoxide levels. ( N, O ) Representative images and quantification of mitochondrial membrane potential (ΔΨm) assessed by JC-1 staining (red: J-aggregates, high ΔΨm; green: monomers, low ΔΨm). ( P ) Representative TTC-stained brain sections from MCAO mice treated with MIGs in the presence or absence of the Rap1 inhibitor GGTI298. ( Q ) Quantitative analysis of infarct volume. Data are presented as mean ± SD from at least three independent experiments (cells) or n = 6 mice per group. * p < 0.05, ** p < 0.01, *** p < 0.001
Rap1 Inhibition, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rap1/GGTI298/pmc13455202-92-1-14
Average 95 stars, based on 1 article reviews
rap1 inhibition - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier

rap1  (Tanabe)
86
Tanabe rap1
M2 microglia-derived migrasome-enriched EVs activate the <t>cAMP/EPAC1/Rap1</t> pathway to improve mitochondrial function in microglia. ( A ) Heatmap of differentially expressed genes in ipsilateral brain tissue between the MCAO and MIGs groups. ( B ) Volcano plot of DEGs between the MCAO and MIGs groups. ( C ) KEGG pathway enrichment analysis. The top enriched pathways are shown, with the cAMP signaling pathway and Rap1 signaling pathway highlighted. ( D ) cAMP levels in BV2 cells. ( E-G ) Representative immunofluorescence image and quantitative analysis of EPAC1 and Rap1 in BV2 cells. ( H, I ) Western blot analysis and quantification of EPAC1 and Rap1 protein expression in BV2 cells. ( J ) Representative TEM images of mitochondria in BV2 cells. ( K ) Representative images and quantification of mitochondrial mass. (L, M ) Representative images and quantification of mitochondrial superoxide levels. ( N, O ) Representative images and quantification of mitochondrial membrane potential (ΔΨm) assessed by JC-1 staining (red: J-aggregates, high ΔΨm; green: monomers, low ΔΨm). ( P ) Representative TTC-stained brain sections from MCAO mice treated with MIGs in the presence or absence of the Rap1 inhibitor GGTI298. ( Q ) Quantitative analysis of infarct volume. Data are presented as mean ± SD from at least three independent experiments (cells) or n = 6 mice per group. * p < 0.05, ** p < 0.01, *** p < 0.001
Rap1, supplied by Tanabe, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rap1/rap1/pm42114705-85-0-13
Average 86 stars, based on 1 article reviews
rap1 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

93
Fortis Life Sciences rabbit polyclonal anti rap1
M2 microglia-derived migrasome-enriched EVs activate the <t>cAMP/EPAC1/Rap1</t> pathway to improve mitochondrial function in microglia. ( A ) Heatmap of differentially expressed genes in ipsilateral brain tissue between the MCAO and MIGs groups. ( B ) Volcano plot of DEGs between the MCAO and MIGs groups. ( C ) KEGG pathway enrichment analysis. The top enriched pathways are shown, with the cAMP signaling pathway and Rap1 signaling pathway highlighted. ( D ) cAMP levels in BV2 cells. ( E-G ) Representative immunofluorescence image and quantitative analysis of EPAC1 and Rap1 in BV2 cells. ( H, I ) Western blot analysis and quantification of EPAC1 and Rap1 protein expression in BV2 cells. ( J ) Representative TEM images of mitochondria in BV2 cells. ( K ) Representative images and quantification of mitochondrial mass. (L, M ) Representative images and quantification of mitochondrial superoxide levels. ( N, O ) Representative images and quantification of mitochondrial membrane potential (ΔΨm) assessed by JC-1 staining (red: J-aggregates, high ΔΨm; green: monomers, low ΔΨm). ( P ) Representative TTC-stained brain sections from MCAO mice treated with MIGs in the presence or absence of the Rap1 inhibitor GGTI298. ( Q ) Quantitative analysis of infarct volume. Data are presented as mean ± SD from at least three independent experiments (cells) or n = 6 mice per group. * p < 0.05, ** p < 0.01, *** p < 0.001
Rabbit Polyclonal Anti Rap1, supplied by Fortis Life Sciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rap1/RAP1+Antibody/pmc13269807-26-0-4
Average 93 stars, based on 1 article reviews
rabbit polyclonal anti rap1 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

96
Bio-Rad buffer b trf2 rap1
<t>TRF2–RAP1</t> <t>interaction</t> enhances TRF2’s binding to telomere R-loops. ( A, B ) TRF2 binds 32 P-TERRA and telomere R-loops. His-tagged TRF2 protein (0–80 nM) was incubated with 5 nM radiolabeled TERRA (A) or telomere R-loops (B). The mobility shifts of the TRF2–RNA complex were analyzed by 10% native polyacrylamide gel electrophoresis. ( C ) Quantification of the binding data in panels (A, B). The error bars represent mean values ± SD of data from three independent experiments. ( D ) TRF2–RAP1 interaction enhances TRF2’s binding to telomere R-loops. Purified WT TRF2, mutants TRF2 ΔB , TRF2 L288R , TRF2 ΔB,L288R , and WT RAP1 alone or in the indicated combinations were tested for telomere R-loop binding. The mobility shift of the TRF2–RNA complexes was analyzed by 10% polyacrylamide gels. ( E, F ) Quantification of the R-loop binding data in panel (D). Error bars represent mean values ± SD of data from three independent experiments. ( G ) TRF2 (50, 100, 150, 200, and 250 nM) without or with RAP1 (100 nM) was incubated with telomere dsDNA and R-loops (10 nM each) to determine relative binding affinities. The ability of TRF2 or TRF2–RAP1 to bind to these nucleic acid substrates was analyzed by 10% polyacrylamide gels. ( H, I ) The R-loop and dsDNA binding data in panel (G) were quantified and plotted. Error bars represent mean values ± SD of data from three independent experiments.
Buffer B Trf2 Rap1, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rap1/Micro+Bio-Spin+6/pmc13036488-88-19-16
Average 96 stars, based on 1 article reviews
buffer b trf2 rap1 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier

94
Santa Cruz Biotechnology rap1
<t>TRF2–RAP1</t> <t>interaction</t> enhances TRF2’s binding to telomere R-loops. ( A, B ) TRF2 binds 32 P-TERRA and telomere R-loops. His-tagged TRF2 protein (0–80 nM) was incubated with 5 nM radiolabeled TERRA (A) or telomere R-loops (B). The mobility shifts of the TRF2–RNA complex were analyzed by 10% native polyacrylamide gel electrophoresis. ( C ) Quantification of the binding data in panels (A, B). The error bars represent mean values ± SD of data from three independent experiments. ( D ) TRF2–RAP1 interaction enhances TRF2’s binding to telomere R-loops. Purified WT TRF2, mutants TRF2 ΔB , TRF2 L288R , TRF2 ΔB,L288R , and WT RAP1 alone or in the indicated combinations were tested for telomere R-loop binding. The mobility shift of the TRF2–RNA complexes was analyzed by 10% polyacrylamide gels. ( E, F ) Quantification of the R-loop binding data in panel (D). Error bars represent mean values ± SD of data from three independent experiments. ( G ) TRF2 (50, 100, 150, 200, and 250 nM) without or with RAP1 (100 nM) was incubated with telomere dsDNA and R-loops (10 nM each) to determine relative binding affinities. The ability of TRF2 or TRF2–RAP1 to bind to these nucleic acid substrates was analyzed by 10% polyacrylamide gels. ( H, I ) The R-loop and dsDNA binding data in panel (G) were quantified and plotted. Error bars represent mean values ± SD of data from three independent experiments.
Rap1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rap1/RAP1+Antibody/pmc12993239-119-51-53
Average 94 stars, based on 1 article reviews
rap1 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

86
Cell Signaling Technology Inc rap1 antibody
<t>TRF2–RAP1</t> <t>interaction</t> enhances TRF2’s binding to telomere R-loops. ( A, B ) TRF2 binds 32 P-TERRA and telomere R-loops. His-tagged TRF2 protein (0–80 nM) was incubated with 5 nM radiolabeled TERRA (A) or telomere R-loops (B). The mobility shifts of the TRF2–RNA complex were analyzed by 10% native polyacrylamide gel electrophoresis. ( C ) Quantification of the binding data in panels (A, B). The error bars represent mean values ± SD of data from three independent experiments. ( D ) TRF2–RAP1 interaction enhances TRF2’s binding to telomere R-loops. Purified WT TRF2, mutants TRF2 ΔB , TRF2 L288R , TRF2 ΔB,L288R , and WT RAP1 alone or in the indicated combinations were tested for telomere R-loop binding. The mobility shift of the TRF2–RNA complexes was analyzed by 10% polyacrylamide gels. ( E, F ) Quantification of the R-loop binding data in panel (D). Error bars represent mean values ± SD of data from three independent experiments. ( G ) TRF2 (50, 100, 150, 200, and 250 nM) without or with RAP1 (100 nM) was incubated with telomere dsDNA and R-loops (10 nM each) to determine relative binding affinities. The ability of TRF2 or TRF2–RAP1 to bind to these nucleic acid substrates was analyzed by 10% polyacrylamide gels. ( H, I ) The R-loop and dsDNA binding data in panel (G) were quantified and plotted. Error bars represent mean values ± SD of data from three independent experiments.
Rap1 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rap1/pm41897459-76-62-64
Average 86 stars, based on 1 article reviews
rap1 antibody - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

93
Cell Signaling Technology Inc rap1 assay
<t>TRF2–RAP1</t> <t>interaction</t> enhances TRF2’s binding to telomere R-loops. ( A, B ) TRF2 binds 32 P-TERRA and telomere R-loops. His-tagged TRF2 protein (0–80 nM) was incubated with 5 nM radiolabeled TERRA (A) or telomere R-loops (B). The mobility shifts of the TRF2–RNA complex were analyzed by 10% native polyacrylamide gel electrophoresis. ( C ) Quantification of the binding data in panels (A, B). The error bars represent mean values ± SD of data from three independent experiments. ( D ) TRF2–RAP1 interaction enhances TRF2’s binding to telomere R-loops. Purified WT TRF2, mutants TRF2 ΔB , TRF2 L288R , TRF2 ΔB,L288R , and WT RAP1 alone or in the indicated combinations were tested for telomere R-loop binding. The mobility shift of the TRF2–RNA complexes was analyzed by 10% polyacrylamide gels. ( E, F ) Quantification of the R-loop binding data in panel (D). Error bars represent mean values ± SD of data from three independent experiments. ( G ) TRF2 (50, 100, 150, 200, and 250 nM) without or with RAP1 (100 nM) was incubated with telomere dsDNA and R-loops (10 nM each) to determine relative binding affinities. The ability of TRF2 or TRF2–RAP1 to bind to these nucleic acid substrates was analyzed by 10% polyacrylamide gels. ( H, I ) The R-loop and dsDNA binding data in panel (G) were quantified and plotted. Error bars represent mean values ± SD of data from three independent experiments.
Rap1 Assay, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rap1/Active+Rap1+Detection+Kit/us12576114-738-24-26
Average 93 stars, based on 1 article reviews
rap1 assay - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

93
Cell Signaling Technology Inc rap1
<t>TRF2–RAP1</t> <t>interaction</t> enhances TRF2’s binding to telomere R-loops. ( A, B ) TRF2 binds 32 P-TERRA and telomere R-loops. His-tagged TRF2 protein (0–80 nM) was incubated with 5 nM radiolabeled TERRA (A) or telomere R-loops (B). The mobility shifts of the TRF2–RNA complex were analyzed by 10% native polyacrylamide gel electrophoresis. ( C ) Quantification of the binding data in panels (A, B). The error bars represent mean values ± SD of data from three independent experiments. ( D ) TRF2–RAP1 interaction enhances TRF2’s binding to telomere R-loops. Purified WT TRF2, mutants TRF2 ΔB , TRF2 L288R , TRF2 ΔB,L288R , and WT RAP1 alone or in the indicated combinations were tested for telomere R-loop binding. The mobility shift of the TRF2–RNA complexes was analyzed by 10% polyacrylamide gels. ( E, F ) Quantification of the R-loop binding data in panel (D). Error bars represent mean values ± SD of data from three independent experiments. ( G ) TRF2 (50, 100, 150, 200, and 250 nM) without or with RAP1 (100 nM) was incubated with telomere dsDNA and R-loops (10 nM each) to determine relative binding affinities. The ability of TRF2 or TRF2–RAP1 to bind to these nucleic acid substrates was analyzed by 10% polyacrylamide gels. ( H, I ) The R-loop and dsDNA binding data in panel (G) were quantified and plotted. Error bars represent mean values ± SD of data from three independent experiments.
Rap1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rap1/Rap1A%2FRap1B+Rabbit+mAb/us12576114-753-9-10
Average 93 stars, based on 1 article reviews
rap1 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

Image Search Results


M2 microglia-derived migrasome-enriched EVs activate the cAMP/EPAC1/Rap1 pathway to improve mitochondrial function in microglia. ( A ) Heatmap of differentially expressed genes in ipsilateral brain tissue between the MCAO and MIGs groups. ( B ) Volcano plot of DEGs between the MCAO and MIGs groups. ( C ) KEGG pathway enrichment analysis. The top enriched pathways are shown, with the cAMP signaling pathway and Rap1 signaling pathway highlighted. ( D ) cAMP levels in BV2 cells. ( E-G ) Representative immunofluorescence image and quantitative analysis of EPAC1 and Rap1 in BV2 cells. ( H, I ) Western blot analysis and quantification of EPAC1 and Rap1 protein expression in BV2 cells. ( J ) Representative TEM images of mitochondria in BV2 cells. ( K ) Representative images and quantification of mitochondrial mass. (L, M ) Representative images and quantification of mitochondrial superoxide levels. ( N, O ) Representative images and quantification of mitochondrial membrane potential (ΔΨm) assessed by JC-1 staining (red: J-aggregates, high ΔΨm; green: monomers, low ΔΨm). ( P ) Representative TTC-stained brain sections from MCAO mice treated with MIGs in the presence or absence of the Rap1 inhibitor GGTI298. ( Q ) Quantitative analysis of infarct volume. Data are presented as mean ± SD from at least three independent experiments (cells) or n = 6 mice per group. * p < 0.05, ** p < 0.01, *** p < 0.001

Journal: Journal of Nanobiotechnology

Article Title: M2 microglia-derived migrasome-enriched extracellular vesicles restore mitochondrial homeostasis to orchestrate neurovascular unit recovery after ischemic stroke

doi: 10.1186/s12951-026-04643-4

Figure Lengend Snippet: M2 microglia-derived migrasome-enriched EVs activate the cAMP/EPAC1/Rap1 pathway to improve mitochondrial function in microglia. ( A ) Heatmap of differentially expressed genes in ipsilateral brain tissue between the MCAO and MIGs groups. ( B ) Volcano plot of DEGs between the MCAO and MIGs groups. ( C ) KEGG pathway enrichment analysis. The top enriched pathways are shown, with the cAMP signaling pathway and Rap1 signaling pathway highlighted. ( D ) cAMP levels in BV2 cells. ( E-G ) Representative immunofluorescence image and quantitative analysis of EPAC1 and Rap1 in BV2 cells. ( H, I ) Western blot analysis and quantification of EPAC1 and Rap1 protein expression in BV2 cells. ( J ) Representative TEM images of mitochondria in BV2 cells. ( K ) Representative images and quantification of mitochondrial mass. (L, M ) Representative images and quantification of mitochondrial superoxide levels. ( N, O ) Representative images and quantification of mitochondrial membrane potential (ΔΨm) assessed by JC-1 staining (red: J-aggregates, high ΔΨm; green: monomers, low ΔΨm). ( P ) Representative TTC-stained brain sections from MCAO mice treated with MIGs in the presence or absence of the Rap1 inhibitor GGTI298. ( Q ) Quantitative analysis of infarct volume. Data are presented as mean ± SD from at least three independent experiments (cells) or n = 6 mice per group. * p < 0.05, ** p < 0.01, *** p < 0.001

Article Snippet: For Rap1 inhibition experiments, mice received an intraperitoneal injection of GGTI298 (25 μM/kg; HY-100876, MCE, USA) 30 min prior to reperfusion.

Techniques: Derivative Assay, Immunofluorescence, Western Blot, Expressing, Membrane, Staining

TRF2–RAP1 interaction enhances TRF2’s binding to telomere R-loops. ( A, B ) TRF2 binds 32 P-TERRA and telomere R-loops. His-tagged TRF2 protein (0–80 nM) was incubated with 5 nM radiolabeled TERRA (A) or telomere R-loops (B). The mobility shifts of the TRF2–RNA complex were analyzed by 10% native polyacrylamide gel electrophoresis. ( C ) Quantification of the binding data in panels (A, B). The error bars represent mean values ± SD of data from three independent experiments. ( D ) TRF2–RAP1 interaction enhances TRF2’s binding to telomere R-loops. Purified WT TRF2, mutants TRF2 ΔB , TRF2 L288R , TRF2 ΔB,L288R , and WT RAP1 alone or in the indicated combinations were tested for telomere R-loop binding. The mobility shift of the TRF2–RNA complexes was analyzed by 10% polyacrylamide gels. ( E, F ) Quantification of the R-loop binding data in panel (D). Error bars represent mean values ± SD of data from three independent experiments. ( G ) TRF2 (50, 100, 150, 200, and 250 nM) without or with RAP1 (100 nM) was incubated with telomere dsDNA and R-loops (10 nM each) to determine relative binding affinities. The ability of TRF2 or TRF2–RAP1 to bind to these nucleic acid substrates was analyzed by 10% polyacrylamide gels. ( H, I ) The R-loop and dsDNA binding data in panel (G) were quantified and plotted. Error bars represent mean values ± SD of data from three independent experiments.

Journal: Nucleic Acids Research

Article Title: TRF2–RAP1 inhibits homology-directed repair of telomeres by promoting BLM-mediated removal of telomere R-loops

doi: 10.1093/nar/gkag272

Figure Lengend Snippet: TRF2–RAP1 interaction enhances TRF2’s binding to telomere R-loops. ( A, B ) TRF2 binds 32 P-TERRA and telomere R-loops. His-tagged TRF2 protein (0–80 nM) was incubated with 5 nM radiolabeled TERRA (A) or telomere R-loops (B). The mobility shifts of the TRF2–RNA complex were analyzed by 10% native polyacrylamide gel electrophoresis. ( C ) Quantification of the binding data in panels (A, B). The error bars represent mean values ± SD of data from three independent experiments. ( D ) TRF2–RAP1 interaction enhances TRF2’s binding to telomere R-loops. Purified WT TRF2, mutants TRF2 ΔB , TRF2 L288R , TRF2 ΔB,L288R , and WT RAP1 alone or in the indicated combinations were tested for telomere R-loop binding. The mobility shift of the TRF2–RNA complexes was analyzed by 10% polyacrylamide gels. ( E, F ) Quantification of the R-loop binding data in panel (D). Error bars represent mean values ± SD of data from three independent experiments. ( G ) TRF2 (50, 100, 150, 200, and 250 nM) without or with RAP1 (100 nM) was incubated with telomere dsDNA and R-loops (10 nM each) to determine relative binding affinities. The ability of TRF2 or TRF2–RAP1 to bind to these nucleic acid substrates was analyzed by 10% polyacrylamide gels. ( H, I ) The R-loop and dsDNA binding data in panel (G) were quantified and plotted. Error bars represent mean values ± SD of data from three independent experiments.

Article Snippet: The deproteinized reaction mixtures by SDS and proteinase K were passed through Micro Bio-Spin 6 Column (Bio-Rad), equilibrated with buffer B. TRF2–RAP1 (50 nM) was pre-incubated with the D/R-loop substrate (2.5 nM) on ice for 10 min. Then BLM (20–80 nM) was added and incubated at 37°C for 20 min.

Techniques: Binding Assay, Incubation, Polyacrylamide Gel Electrophoresis, Purification, Mobility Shift

TRF2–RAP1 promotes BLM-mediated unwinding of telomere R-loops. ( A ) (Top) Schematic of the oligo-based telomere R-loop unwinding assay. Telomere R-loop substrates were generated by hybridizing 32 P-labeled TERRA and two telomere DNA fragments (TDR2 and TDR3). TRF2 and/or RAP1 were pre-incubated with the R-loops and then BLM was added to the reaction, and the complex was resolved by 10% native polyacrylamide gel electrophoresis to monitor for R-loop unwinding. Displacement of the invading radiolabeled TERRA from R-loops indicates that R-loop unwinding. (Bottom) The TRF2–RAP1 complex promotes BLM-mediated unwinding of telomere R-loops. The effects of TRF2 alone (40, 80 nM) or in combination with RAP1 (20, 40, 80 nM) on the ability of BLM (20 nM) to unwind telomere R-loops were examined. 32 P-labeled TERRA and R-loops were resolved by native-PAGE and shown in lanes 1 and 2. ( B ) Quantification of BLM-mediated R-loop unwinding reactions in panel (A). The percentages of unwound R-loops are shown as mean values ± SD from three independent experiments. Statistical evaluation was performed by ANOVA test. ns: non-significant ( P = .9485); **** P < .0001. ( C ) The TRF2 basic domain is required for efficient unwinding of telomere R-loops. The effect of WT TRF2, TRF2 ΔB , TRF2 ΔB,L288R , and RAP1 to enhance BLM-mediated telomere R-loop unwinding was examined. The sizes of 32 P-labeled TERRA and R-loops were resolved by native-PAGE, as shown in lanes 1 and 2. ( D ) Quantification of BLM-mediated R-loop unwinding reactions in panel (C). The percentages of unwound R-loops are shown as mean values ± SD from three independent experiments. Statistical evaluation was performed by ANOVA test. **** P < .0001. ( E ) The TRF2–BLM interaction enhances telomere R-loop unwinding. The effect of TRF2–RAP1 on the ability of WT and mutant BLM (3A or P690L) to unwind telomere R-loops was tested as in Fig. . 32 P-labeled TERRA and R-loops were loaded as size markers (lanes 1 and 2) and resolved by native-PAGE. ( F ) Quantification of the percentages of unwound R-loops in panel (E) as mean ± SD from three independent experiments. Statistical evaluation was performed by ANOVA test. ns: non-significant ( P = .98); **** P < .0001.

Journal: Nucleic Acids Research

Article Title: TRF2–RAP1 inhibits homology-directed repair of telomeres by promoting BLM-mediated removal of telomere R-loops

doi: 10.1093/nar/gkag272

Figure Lengend Snippet: TRF2–RAP1 promotes BLM-mediated unwinding of telomere R-loops. ( A ) (Top) Schematic of the oligo-based telomere R-loop unwinding assay. Telomere R-loop substrates were generated by hybridizing 32 P-labeled TERRA and two telomere DNA fragments (TDR2 and TDR3). TRF2 and/or RAP1 were pre-incubated with the R-loops and then BLM was added to the reaction, and the complex was resolved by 10% native polyacrylamide gel electrophoresis to monitor for R-loop unwinding. Displacement of the invading radiolabeled TERRA from R-loops indicates that R-loop unwinding. (Bottom) The TRF2–RAP1 complex promotes BLM-mediated unwinding of telomere R-loops. The effects of TRF2 alone (40, 80 nM) or in combination with RAP1 (20, 40, 80 nM) on the ability of BLM (20 nM) to unwind telomere R-loops were examined. 32 P-labeled TERRA and R-loops were resolved by native-PAGE and shown in lanes 1 and 2. ( B ) Quantification of BLM-mediated R-loop unwinding reactions in panel (A). The percentages of unwound R-loops are shown as mean values ± SD from three independent experiments. Statistical evaluation was performed by ANOVA test. ns: non-significant ( P = .9485); **** P < .0001. ( C ) The TRF2 basic domain is required for efficient unwinding of telomere R-loops. The effect of WT TRF2, TRF2 ΔB , TRF2 ΔB,L288R , and RAP1 to enhance BLM-mediated telomere R-loop unwinding was examined. The sizes of 32 P-labeled TERRA and R-loops were resolved by native-PAGE, as shown in lanes 1 and 2. ( D ) Quantification of BLM-mediated R-loop unwinding reactions in panel (C). The percentages of unwound R-loops are shown as mean values ± SD from three independent experiments. Statistical evaluation was performed by ANOVA test. **** P < .0001. ( E ) The TRF2–BLM interaction enhances telomere R-loop unwinding. The effect of TRF2–RAP1 on the ability of WT and mutant BLM (3A or P690L) to unwind telomere R-loops was tested as in Fig. . 32 P-labeled TERRA and R-loops were loaded as size markers (lanes 1 and 2) and resolved by native-PAGE. ( F ) Quantification of the percentages of unwound R-loops in panel (E) as mean ± SD from three independent experiments. Statistical evaluation was performed by ANOVA test. ns: non-significant ( P = .98); **** P < .0001.

Article Snippet: The deproteinized reaction mixtures by SDS and proteinase K were passed through Micro Bio-Spin 6 Column (Bio-Rad), equilibrated with buffer B. TRF2–RAP1 (50 nM) was pre-incubated with the D/R-loop substrate (2.5 nM) on ice for 10 min. Then BLM (20–80 nM) was added and incubated at 37°C for 20 min.

Techniques: Generated, Labeling, Incubation, Polyacrylamide Gel Electrophoresis, Clear Native PAGE, Mutagenesis

BLM preferentially releases TERRA over ssDNA from telomere D/R-loops. ( A ) Schematic of the assay used to measure how TRF2–RAP1 promotes BLM-mediated unwinding of RAD51/ssDNA and RAD51AP1/TERRA-generated telomeric D/R-loops. Telomere D/R-loops were generated by incubating RAD51 with IRDye-700-labeled telomere ssDNA (red), RAD51AP1 with IRDye-800-labeled TERRA (green), and telomere plasmids together as described in Fig. . Native plasmid-sized telomere D/R-loops were obtained after deproteinization and column purification. BLM with or without TRF2–RAP1 was then incubated with these D/R-loops, and ssDNA, TERRA release, or D/R-loop unwinding was analyzed by 1% agarose gels. ( B ) BLM preferentially releases TERRA over ssDNA from telomere D/R-loop. BLM (20, 40, 80 nM) was tested for its ability to unwind telomere D/R-loops or TRF2–RAP1-bound D/R-loops. ssDNA, TERRA release, or D/R-loop unwinding was analyzed by 1% agarose gels. The unwinding of telomere D/R-loops by BLM was enhanced by TRF2–RAP1. ( C ) Quantification of the amount of D- and R-loops relative to the negative control (no proteins, lane 1). Data were plotted as mean ± SD from three independent experiments. Statistical evaluation was performed by ANOVA test. * P = .02282; ** P = .001278; *** P = .0007284; **** P < .0001. ( D ) The effects of TRF2–RAP1 on WT BLM, the helicase-dead BLM K695R or BLM mutants on D/R-loop unwinding were tested as in panel (B). In contrast to WT BLM, TRF2–RAP1 cannot enhance BLM ’s ability to unwind telomere D/R-loops. D/R-loop unwinding was analyzed by 1% agarose gels. ( E ) Quantification of the relative amounts of D-loops or R-loops to the control without proteins (lane 1) is shown as mean ± SD from three independent experiments. ANOVA test was used to evaluate statistical differences. ns: non-significant ( P = .15; .4147; .8026); ** P = .001193; *** P = .000158.

Journal: Nucleic Acids Research

Article Title: TRF2–RAP1 inhibits homology-directed repair of telomeres by promoting BLM-mediated removal of telomere R-loops

doi: 10.1093/nar/gkag272

Figure Lengend Snippet: BLM preferentially releases TERRA over ssDNA from telomere D/R-loops. ( A ) Schematic of the assay used to measure how TRF2–RAP1 promotes BLM-mediated unwinding of RAD51/ssDNA and RAD51AP1/TERRA-generated telomeric D/R-loops. Telomere D/R-loops were generated by incubating RAD51 with IRDye-700-labeled telomere ssDNA (red), RAD51AP1 with IRDye-800-labeled TERRA (green), and telomere plasmids together as described in Fig. . Native plasmid-sized telomere D/R-loops were obtained after deproteinization and column purification. BLM with or without TRF2–RAP1 was then incubated with these D/R-loops, and ssDNA, TERRA release, or D/R-loop unwinding was analyzed by 1% agarose gels. ( B ) BLM preferentially releases TERRA over ssDNA from telomere D/R-loop. BLM (20, 40, 80 nM) was tested for its ability to unwind telomere D/R-loops or TRF2–RAP1-bound D/R-loops. ssDNA, TERRA release, or D/R-loop unwinding was analyzed by 1% agarose gels. The unwinding of telomere D/R-loops by BLM was enhanced by TRF2–RAP1. ( C ) Quantification of the amount of D- and R-loops relative to the negative control (no proteins, lane 1). Data were plotted as mean ± SD from three independent experiments. Statistical evaluation was performed by ANOVA test. * P = .02282; ** P = .001278; *** P = .0007284; **** P < .0001. ( D ) The effects of TRF2–RAP1 on WT BLM, the helicase-dead BLM K695R or BLM mutants on D/R-loop unwinding were tested as in panel (B). In contrast to WT BLM, TRF2–RAP1 cannot enhance BLM ’s ability to unwind telomere D/R-loops. D/R-loop unwinding was analyzed by 1% agarose gels. ( E ) Quantification of the relative amounts of D-loops or R-loops to the control without proteins (lane 1) is shown as mean ± SD from three independent experiments. ANOVA test was used to evaluate statistical differences. ns: non-significant ( P = .15; .4147; .8026); ** P = .001193; *** P = .000158.

Article Snippet: The deproteinized reaction mixtures by SDS and proteinase K were passed through Micro Bio-Spin 6 Column (Bio-Rad), equilibrated with buffer B. TRF2–RAP1 (50 nM) was pre-incubated with the D/R-loop substrate (2.5 nM) on ice for 10 min. Then BLM (20–80 nM) was added and incubated at 37°C for 20 min.

Techniques: Generated, Labeling, Plasmid Preparation, Purification, Incubation, Negative Control, Control

TRF2–RAP1–BLM is required to resolve telomere R-loops in U2OS cells. ( A ) U2OS cells expressing TRF2 ΔB, L288R were treated with shControl, shBLM, or shTRF2. Immunofluorescence-FISH analysis of cells containing UTs (PNA telomere probe, red) co-localized with R-loops (S9.6 antibody, green) and DAPI-stained nuclei (blue). White arrow: co-localization of R-loops on UTs. U2OS cells expressing shBLM-resistant WT BLM cDNA and indicated BLM mutants were treated with shBLM, shTRF2, and TRF2 ΔB, L288R . IF-FISH analysis was performed to detect UT/R-loop co-localization. White arrow: co-localization of R-loops on UTs. ( C ) Quantification of data from Fig. and , showing the number of UT/R-loop colocalizations per U2OS cell. Data from three independent experiments is shown as mean ± SEM from minimum 200 nuclei per experiment. Statistical evaluation was performed by one-way ANOVA test. ns: non-significant ( P > .9999); ** P = .0032; .0035; .0062; .0092; .0052; **** P < .0001. ( D ) Model showing that TRF2–RAP1 inhibits telomere HDR by promoting BLM-mediated telomere R-loop removal. RAD51AP1 and TERRA-dependent R-loops promote RAD51-mediated telomere D-loop formation. The TRF2–RAP1 complex and TRF2–BLM interaction are required to promote BLM helicase-mediated unwinding of telomere R-loops and then D-loops. The RAP1–TRF2–BLM complex represses HDR on telomeres by removing R-loops to inhibit telomere D-loop formation.

Journal: Nucleic Acids Research

Article Title: TRF2–RAP1 inhibits homology-directed repair of telomeres by promoting BLM-mediated removal of telomere R-loops

doi: 10.1093/nar/gkag272

Figure Lengend Snippet: TRF2–RAP1–BLM is required to resolve telomere R-loops in U2OS cells. ( A ) U2OS cells expressing TRF2 ΔB, L288R were treated with shControl, shBLM, or shTRF2. Immunofluorescence-FISH analysis of cells containing UTs (PNA telomere probe, red) co-localized with R-loops (S9.6 antibody, green) and DAPI-stained nuclei (blue). White arrow: co-localization of R-loops on UTs. U2OS cells expressing shBLM-resistant WT BLM cDNA and indicated BLM mutants were treated with shBLM, shTRF2, and TRF2 ΔB, L288R . IF-FISH analysis was performed to detect UT/R-loop co-localization. White arrow: co-localization of R-loops on UTs. ( C ) Quantification of data from Fig. and , showing the number of UT/R-loop colocalizations per U2OS cell. Data from three independent experiments is shown as mean ± SEM from minimum 200 nuclei per experiment. Statistical evaluation was performed by one-way ANOVA test. ns: non-significant ( P > .9999); ** P = .0032; .0035; .0062; .0092; .0052; **** P < .0001. ( D ) Model showing that TRF2–RAP1 inhibits telomere HDR by promoting BLM-mediated telomere R-loop removal. RAD51AP1 and TERRA-dependent R-loops promote RAD51-mediated telomere D-loop formation. The TRF2–RAP1 complex and TRF2–BLM interaction are required to promote BLM helicase-mediated unwinding of telomere R-loops and then D-loops. The RAP1–TRF2–BLM complex represses HDR on telomeres by removing R-loops to inhibit telomere D-loop formation.

Article Snippet: The deproteinized reaction mixtures by SDS and proteinase K were passed through Micro Bio-Spin 6 Column (Bio-Rad), equilibrated with buffer B. TRF2–RAP1 (50 nM) was pre-incubated with the D/R-loop substrate (2.5 nM) on ice for 10 min. Then BLM (20–80 nM) was added and incubated at 37°C for 20 min.

Techniques: Expressing, Immunofluorescence, Staining